Emany Sravan Kumar 4

What Happened

• Emany Sravan Kumar, Chief Financial Officer of Beam Therapeutics (BEAM), was granted a 63,500-share derivative award on January 31, 2026. The reported acquisition price is $0 (a typical grant/option award entry on Form 4), and no shares were sold as part of this filing. This is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-31; Form 4 filed: 2026-02-02 (filing appears within the required reporting window).
• Transaction type: Award/Grant (derivative instrument reported as A).
• Shares granted: 63,500; reported price per share: $0 (grant/derivative entry).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The stock option vests in equal monthly installments over the subsequent 48 months, subject to continued service with Beam.
• No 10b5-1 plan, tax withholding, or cashless exercise noted in this filing.

Context

• This filing reports an equity compensation grant (stock option) to the CFO. Such awards are common as part of executive pay packages and do not represent an immediate purchase or sale of stock; vesting over 48 months means the economic benefit is realized over time and is contingent on continued service. The filing shows no immediate disposition of shares.